SCHEMBL5378065

SCHEMBL5378065

CCCc1ccc(-c2nc(-c3ccc(C=O)cc3)no2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 7/20 0.58
NPC1 O15118 6/20 0.58
RAB9A P51151 6/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
ALDH1A1 P00352 3/20 0.58
MAPT P10636 3/20 0.58
NFKB1 P19838 2/20 0.58
NFKB2 Q00653 2/20 0.58
RELA Q04206 2/20 0.58
NPSR1 Q6W5P4 1/20 0.58
S1PR3 Q99500 4/20 0.55
S1PR5 Q9H228 3/20 0.55
S1PR4 O95977 2/20 0.55
LMNA P02545 1/20 0.52
TP53 P04637 1/20 0.52
KDM4E B2RXH2 1/20 0.50
PKM P14618 1/20 0.50
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4742220 0.92 S1PR1 (0.70) S1PR1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4737115 0.90 S1PR1 (0.63) S1PR1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL27767785 0.83 NPC1 (0.48) S1PR1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4787889 0.83 S1PR1 (0.57) S1PR1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3456664 0.82 S1PR1 (0.56) S1PR1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL451098 0.82 S1PR1 (0.56) S1PR1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL5379116 0.82 S1PR1 (0.56) S1PR1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL1312371 0.81 S1PR1 (0.62) S1PR1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL22280480 0.81 SMN1; SMN2 (0.64) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL3456771 0.81 NPC1 (0.66) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199142-B2 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists MERCK & CO., INC. (US) 2007-04-03 US disclosed
US-20050245575-A1 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists MERCK & CO., INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245575-A1 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists EDNRA, OXGR1, EDNRB S1PR1 217/4885NPC1 1817/4885RAB9A 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.